{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:28Z","timestamp":1786982668629,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-026-01655-8","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:49:15Z","timestamp":1770814155000},"page":"1617-1634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry"],"prefix":"10.1007","volume":"16","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-8564","authenticated-orcid":false,"given":"Xinghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"16","key":"1655_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165370","volume":"12","author":"C Gu","year":"2023","unstructured":"Gu C, Yao X, Li W. Burden of disease; the current status of the diagnosis and management of atopic dermatitis in China. J Clin Med. 2023;12(16):5370.","journal-title":"J Clin Med"},{"issue":"5","key":"1655_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/CM9.0000000000002560","volume":"136","author":"D Mao","year":"2023","unstructured":"Mao D, Li J, Liu S, et al. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study. Chin Med J. 2023;136(5):604\u20136.","journal-title":"Chin Med J"},{"key":"1655_CR3","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fpubh.2024.1404721","volume":"12","author":"X Ma","year":"2024","unstructured":"Ma X, Xie Z, Zhou Y, Shi H. Prevalence and risk factors of atopic dermatitis in Chinese children aged 1\u20137\u00a0years: a systematic review and meta analysis. Front Public Health. 2024;12:2024.","journal-title":"Front Public Health"},{"key":"1655_CR4","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2902084","author":"M Savva","year":"2024","unstructured":"Savva M, Papadopoulos NG, Gregoriou S, et al. Recent advancements in the atopic dermatitis mechanism. Front Biosci-Landmark. 2024. https:\/\/doi.org\/10.31083\/j.fbl2902084.","journal-title":"Front Biosci-Landmark"},{"issue":"11","key":"1655_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112927","volume":"10","author":"F Lobefaro","year":"2022","unstructured":"Lobefaro F, Gualdi G, Di Nuzzo S, Amerio P. Atopic dermatitis: clinical aspects and unmet needs. Biomedicines. 2022;10(11):2927.","journal-title":"Biomedicines"},{"issue":"11","key":"1655_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100604","volume":"14","author":"W-l Dong","year":"2021","unstructured":"Dong W-l, An J, Yu M, et al. The prevalence and year lived with disability of atopic dermatitis in China: findings from the global burden of disease study 2019. World Allergy Organ J. 2021;14(11):100604.","journal-title":"World Allergy Organ J"},{"issue":"11","key":"1655_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cea.13487","volume":"49","author":"JP Thyssen","year":"2019","unstructured":"Thyssen JP, Corn G, Wohlfahrt J, Melbye M, Bager P. Retrospective markers of paediatric atopic dermatitis persistence after hospital diagnosis: a nationwide cohort study. Clin Exp Allergy. 2019;49(11):1455\u201363.","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"1655_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase\u00a01 inhibitor abrocitinib for patients with atopic dermatitis: a phase\u00a02 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"1655_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase\u00a03 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"1655_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1655_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"1655_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"key":"1655_CR13","unstructured":"CIBINQO\u2122 (abrocitinib) tablets [package insert]. Shanghai (CN): Pfizer Inc.; 2025 [updated 2025 May\u00a027]. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=17085. Accessed  2025 Jul 18."},{"issue":"3","key":"1655_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, et al. The validated investigator global assessment for atopic dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839\u201346.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1655_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11\u20138.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1655_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000245677","volume":"195","author":"B Kunz","year":"2009","unstructured":"Kunz B, Oranje AP, Labr\u00e8ze L, Stalder J-F, Ring J, Ta\u00efeb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European task force on atopic dermatitis. Dermatology. 2009;195(1):10\u20139.","journal-title":"Dermatology"},{"issue":"4","key":"1655_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1655_CR18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1655_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the atopic dermatitis control tool (ADCT). Curr Med Res Opin. 2020;36(3):367\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1655_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"1655_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"10","key":"1655_CR22","first-page":"1073","volume":"25","author":"SL Canfield","year":"2019","unstructured":"Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the wild west of medication adherence reporting in specialty pharmacy. J Manag Care Spec Pharm. 2019;25(10):1073\u20137.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"1655_CR23","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","volume":"40","author":"M Bergman","year":"2023","unstructured":"Bergman M, Chen N, Thielen R, Zueger P. One-year medication adherence and persistence in rheumatoid arthritis in clinical practice: a retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib. Adv Ther. 2023;40(10):4493\u2013503.","journal-title":"Adv Ther"},{"issue":"10","key":"1655_CR24","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1111\/bcp.15391","volume":"88","author":"LL Dalli","year":"2022","unstructured":"Dalli LL, Kilkenny MF, Arnet I, et al. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN-SPIDERS. Br J Clin Pharmacol. 2022;88(10):4427\u201342.","journal-title":"Br J Clin Pharmacol"},{"issue":"10348","key":"1655_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase\u00a03 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"1","key":"1655_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase\u00a03 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1655_CR27","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1111\/ijd.17344","volume":"63","author":"JC Armario-Hita","year":"2024","unstructured":"Armario-Hita JC, Pereyra-Rodriguez JJ, Gonz\u00e1lez-Quesada A, et al. Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study. Int J Dermatol. 2024;63(11):e289\u201395.","journal-title":"Int J Dermatol"},{"key":"1655_CR28","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.19454","volume":"104","author":"E Kamphuis","year":"2024","unstructured":"Kamphuis E, Boesjes CM, Loman L, et al. Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay registry. Acta Derm Venereol. 2024;104:adv19454.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1655_CR29","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/13543784.2020.1804854","volume":"29","author":"N Nezamololama","year":"2020","unstructured":"Nezamololama N, Crowley EL, Gooderham MJ, Papp K. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert Opin Investig Drugs. 2020;29(9):911\u20137.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1655_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1390","volume":"11","author":"SG Kwatra","year":"2022","unstructured":"Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunol. 2022;11(5):e1390.","journal-title":"Clin Transl Immunol"},{"issue":"10","key":"1655_CR31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/1744666X.2021.1828068","volume":"16","author":"EL Crowley","year":"2020","unstructured":"Crowley EL, Nezamololama N, Papp K, Gooderham MJ. Abrocitinib for the treatment of atopic dermatitis. Expert Rev Clin Immunol. 2020;16(10):955\u201362.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"1655_CR32","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","volume":"149","author":"HC Williams","year":"2022","unstructured":"Williams HC, Schmitt J, Thomas KS, et al. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1899\u2013911.","journal-title":"J Allergy Clin Immunol"},{"key":"1655_CR33","unstructured":"Harmonising Outcome Measures for Eczema. https:\/\/www.homeforeczema.org\/index.aspx. Accessed 2025 Feb 20."},{"key":"1655_CR34","doi-asserted-by":"publisher","unstructured":"Good Publication Practice (GPP). Ann Intern Med. 2022. https:\/\/doi.org\/10.7362\/M22-1460","DOI":"10.7362\/M22-1460"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01655-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01655-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01655-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:00Z","timestamp":1774371960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01655-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1655"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01655-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Li Zhang, Naihui Zhou, Zhouwei Wu, Xuejun Chen, Huilan Zhu, Shanshan Li, Jianwen Han, Guoying Miao, Liming Wu, Rongfei Zhu, Jianyun Lu, Yue Zheng, Xian Jiang, Xianwei Cao, Dehou Yu, Siping Zhang, Yangfeng Ding, Xiaoyong Man, Yong Cui, Ying Li, Xia Dou, and Xinghua Gao declare that they have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with all the ethical principles outlined in the latest World Medical Association Declaration of Helsinki, Good Pharmacoepidemiology Practices, and adhered to applicable legal and regulatory requirements. The study, study protocol, informed consent, and other related documents were reviewed and approved by the institutional review boards\/independent ethics committees of all participating study sites, either verbally or through documented approval (Table\u00a0\n                      \n                      ). Master approval was granted by the Ethics Committee of Medical Science Research of the First Affiliated Hospital of China Medical University (reference number Scientific Research Ethics Review [2023] No. 359). All patients provided written informed consent before performing any investigational activity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}